Nutramax Laboratories Supports Bioiberica Symposium at OARSI 2015 World Congress on Symptomatic Management of Osteoarthritis

EDGEWOOD, Md., May 4, 2015 /PRNewswire/ -- Nutramax Laboratories Consumer Care, Inc. today announced its support of the Bioiberica-sponsored symposium, Symptomatic Management of Osteoarthritis: New Evidence, presented at the Osteoarthritis Research Society International (OARSI) 2015 World Congress in Seattle, Washington on Saturday, May 2. The symposium featured updates on the use of glucosamine/chondroitin sulfate supplementation to maintain joint health, and was presented by prominent global experts in rheumatology and other specialty areas.

"We salute Bioiberica, suppliers of the chondroitin sulfate used in Cosamin^®DS, for assembling a world-class faculty for this symposium, which promises to generate an informative and provocative discussion of emerging clinical evidence," said Dr. Troy Henderson, President and CEO of Nutramax Laboratories Consumer Care, Inc. "Our support of the symposium is in keeping with our efforts to advance the use of high-quality, pharmaceutical grade glucosamine/chondroitin sulfate supplements for joint health, and to encourage the industry's review of new evidence to affect change in clinical guidelines."

Key topics at the symposium covered:

• Drug use and comorbidities in osteoarthritis
  Nigel K. Arden, MBBS, MD, FRCP (symposium co-chair)
  Professor and Director of Musculoskeletal Epidemiology
  The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
  University of Oxford, Oxford, UK

• Cochrane review on chondroitin sulfate
  Jasvinder Singh, MD, MPH
  Professor of Medicine, Birmingham VA Medical Center
  Mayo Clinic College of Medicine, University of Alabama at Birmingham, Birmingham, AL

• Randomized trial of combined glucosamine and chondroitin on inflammation and oxidative stress
  Sandi L. Navarro, PhD
  Research Associate, Cancer Prevention Program
  Division of Public Health Sciences
  Fred Hutchinson Cancer Research Center, Seattle, WA

• MOVES: Multicentre Osteoarthritis interVEntion trial with Sysadoa
  Allen Sawitzke, MD (symposium co-chair)
  Associate Professor in Medicine, Division of Rheumatology
  University of Utah School of Medicine, Salt Lake City, UT

• Question and answer session/concluding remarks
  Nigel K. Arden, MBBS, MD, FRCP
  Allen Sawitzke, MD

Nutramax recently announced plans to assemble a panel of joint health experts to review current American Academy of Orthopaedic Surgeons (AAOS) guidance on the use of glucosamine/chondroitin sulfate supplements for joint health. The panel will focus specifically on the most recent AAOS Evidence-based Guideline for using joint health supplements and provide its recommendation based on a growing body of clinical evidence, including data from the MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa) study, GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial), and a multi-center Brazilian trial comparing Cosamin^®DS (1,500 mg of glucosamine hydrochloride and 1,200 mg of chondroitin sulfate in capsule form) to a Brazilian prescription brand (1,500 mg of glucosamine sulfate and 1,200 mg of chondroitin sulfate) in either a sachet or a capsule formulation. Each of these randomized, controlled trials used high-quality, pharmaceutical-grade glucosamine and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, as did previous clinical studies that were published in 1999 and 2000 using Cosamin^®DS.

"We are excited to bring the very positive results from recent trials of glucosamine and chondroitin sulfate to a wider audience of clinicians," commented Dr. Henderson. "We hope the Bioiberica symposium at OARSI 2015 stimulates a productive, long-term dialog with the AAOS and the rheumatology community as a whole."  

About Cosamin^®DS

Manufactured in Edgewood, MD, Cosamin^®DS is the most researched glucosamine/chondroitin brand.^* Cosamin^®DS uses FCHG49^® glucosamine HCl and TRH122^® chondroitin sulfate, providing exceptional purity in a unique combination of pharmaceutical-grade ingredients not found in other glucosamine/chondroitin combination joint health supplements. 

About the Nutramax Laboratories Family of Companies:
Since 1992, Christian-based Nutramax Laboratories has been developing products for people and their pets. Nutramax Laboratories Consumer Care, Inc., located in Edgewood, Maryland, focuses on researching and developing products to promote consumer health. Located in Lancaster, South Carolina, Nutramax Laboratories Veterinary Sciences, Inc. researches and develops high quality products to support animal health. Nutramax Manufacturing, Inc. manufactures products in both the Maryland and South Carolina locations.

Cosamin^® joint health supplements, including the original Cosamin^®DS and advanced formula Cosamin^®ASU, are available in the U.S. to help support and promote joint health.

^* Based on U.S. studies published in peer-reviewed journals, the Cosamin^® is the most researched glucosamine/chondroitin brand.  

SOURCE Nutramax Laboratories

Related Links

http://www.nutramaxlabs.com